Long‐term outcomes with oral therapy in liver transplant recipients with hepatitis B

• Published in: Clinical transplantation Vol. 33; no. 12; pp. e13740 - n/a
• Main Authors: Saab, Sammy, Song, Dana, Challita, Youssef P., Xiwen Zhou, Tina, Saab, Elena G., Viramontes, Matthew R., Choi, Gina, Durazo, Francisco A., Han, Steven B., El Kabany, Mohammed M., Jackson, Nicholas J., Busuttil, Ronald W.
• Format: Journal Article
• Language: English
• Published: Denmark 01.12.2019
• Subjects: antiviral therapy; hepatitis B; liver transplantation; hepatitis B; antiviral therapy; liver transplantation
• ISSN: 0902-0063; 1399-0012
• DOI: 10.1111/ctr.13740

Background The long‐term impact of oral hepatitis B antiviral therapy in liver transplant (LT) recipients is currently underexplored. The objective of this study was to evaluate how oral antiviral agents impact long‐term renal function in this population. Methods We studied 79 patients who received a LT for hepatitis B and were placed on all‐oral antiviral therapy after withdrawing from hepatitis B immune globulin therapy at the University of California, Los Angeles. Laboratory data were obtained through a retrospective chart review. Univariate analysis and two‐sided t tests were performed. Results The mean (±SD [standard deviation]) age at the time of LT was 65.4 (± 8.2) years. The overall mean (±SD) follow‐up from LT was 6.5 (±3.3) years. 22.8% (18/79) of recipients on all‐oral therapy had worsening of their chronic kidney disease stage, and 17.7% (14/79) had an increase in creatinine of at least 0.3 mg/dL. There were no significant changes in creatinine and GFR in patients while on tenofovir alafenamide. Patient survival was decreased for recipients who developed detectable HBsAg. Conclusion Tenofovir alafenamide appears to have less of an impact on renal function in LT recipients than other antiviral agents. HBV recurrence after transplant is associated with decreased patient survival and remains an important issue to address for LT recipients on oral antiviral therapy.